Form 8-K

8-K — INTELLIGENT BIO SOLUTIONS INC.

Accession: 0001493152-26-022823

Filed: 2026-05-14

Period: 2026-05-13

CIK: 0001725430

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001725430

2026-05-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of Report (Date of Earliest Event Reported): May 13, 2026

INTELLIGENT

BIO SOLUTIONS INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State

Incorporation)

(Commission

File

Number)

(IRS

employer

identification

no.)

135

West, 41st Street, 5th Floor

New

York, NY 10036

(Address

of principal executive offices, including zip code)

Registrant’s

telephone number, including area code: (646) 828-8258

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.01 par value

INBS

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

May 13, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing

financial results for the fiscal quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K.

The

information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities

Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference

in such filing.

Item

9.01 Financial Statements and Exhibits.

No.

Description

99.1

Press release dated May 13, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

May 13, 2026

INTELLIGENT

BIO SOLUTIONS INC.

By:

/s/

Spiro Sakiris

Name:

Spiro

Sakiris

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Intelligent

Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Razor-razorblade

business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales

Nine-month

revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance

Gross

profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month

period

NEW

YORK, May 13, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical

technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational

highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update.

“The

third quarter marked another period of strong commercial execution and revenue growth,” said Harry Simeonidis, President and CEO

at INBS. “Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization

patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and

compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry

into the multi-billion-dollar U.S. market.”

“Our

results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals,” said

Spiro Sakiris, CFO at INBS. “Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies

and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and

cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment

of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance

costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial

momentum continues to accelerate.”

Product

Revenue Breakdown

Three

Months Ended March 31, 2026 (Q3 Fiscal 2026):

● Cartridge

sales of $703,538, up 59% year-over-year, representing 66% of Q3 revenue

● Reader

sales of $139,407, declined 16% year-over-year, reflecting normal quarterly variability following

a strong Q2

● Other

sales of $217,857, up 80% year-over-year, representing 21% of Q3 revenue

● Total

revenue of $1.06 million, up 46% year-over-year

● Gross

profit margin of 50.5%, up from 46.8% in the same period the year prior

● Cash

and cash equivalents of $6.86 million at March 31, 2026, compared to $740,371 at December

31, 2025

Nine

Months Ended March 31, 2026:

● Cartridge

sales of $1.86 million, up 46% year-over-year, representing 61% of nine-month revenue

● Reader

sales of $672,839, up 29% year-over-year

● Other

sales of $535,942, up 31% year-over-year

● Total

revenue of $3.07 million, up 39% year-over-year

● Gross

profit margin of 49.3%, up from 41.3% in the same period the year prior

Fiscal

Third Quarter and Nine Months Ended March 31, 2026, and Subsequent Highlights

● Gross

margin exceeds 50%: Q3 gross profit margin of 50.47%, up from 46.84% in the prior year

period, shows the Company’s ability to scale revenue while improving unit economics.

● Cartridge

revenue up 59% year-over-year: Cartridge sales of $703,538 represented 66% of Q3 revenue,

up from 61% a year ago. The installed base built through prior reader placements is now generating

strong, recurring consumable demand.

● Nine-month

revenue of $3.07 million: Building on the $2.01 million first-half milestone announced

in February 2026, the Company added $1.06 million in revenue in Q3, demonstrating that commercial

momentum is sustained and accelerating.

● Other

sales surge 80% year-over-year: The 80% year-over-year growth in Q3 other sales signals

a broadening product ecosystem and expanding revenue diversification beyond core hardware

and consumables.

● FDA

510(k) regulatory program advancing: The Company continued to make progress on its planned

entry into the multi-billion-dollar U.S. drug screening market, including successfully completing

penetration testing with no major vulnerabilities identified, completing a clinical cut-off

study, and initiating a validation study for the rapid drug screening cartridge targeting

70% faster results.

● New

manufacturing partnership: The Company successfully manufactured and shipped its first

readers under the new partnership, supporting improved margins and production scalability.

● Bouygues

UK partnership: The Company announced a drug-testing rollout with Bouygues UK, part of

the global construction group Bouygues Construction, adding a significant new customer in

the safety-critical sector.

● Eighth

European patent granted: The Company strengthened its European IP portfolio with its

eighth patent grant, further protecting its proprietary fingerprint drug screening technology.

Throughout

the fiscal third quarter, INBS’s growing installed base continued to drive recurring consumable demand. Crossing the 50% gross

margin threshold for the first time is a significant operational milestone, reflecting the increasing contribution of higher-margin cartridge

sales and the efficiencies being realized through the Company’s new manufacturing partnership.

The

Company’s strategic investment in marketing over the nine-month period has proven its value, contributing directly to revenue growth

and successful capital raising, with Q3 marketing spend down 42% year-over-year as brand awareness and market presence continue to mature.

For the nine months ended March 31, 2026, cartridge revenue continued to grow as a proportion of total revenue, with gross margin improvement

of approximately 800 basis points year-over-year underscoring the improving unit economics of the business as it scales.

INBS’s

proprietary Intelligent Fingerprinting Drug Screening System continues to gain traction across more than 27 countries, serving hundreds

of customers in construction, manufacturing, transportation, mining, and other safety-critical industries where non-invasive, rapid drug

screening delivers compelling operational value. With a clearly functioning razor-razorblade commercial model, expanding gross margins,

record nine-month revenue, and a regulatory pathway progressing toward the multi-billion-dollar U.S. market, management believes the

Company is well-positioned to deliver continued growth through the remainder of fiscal 2026. and beyond.

About

Intelligent Bio Solutions Inc.

Intelligent

Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The

Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint

sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system,

the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.

With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical

industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport

and logistics firms, mining, drug treatment organizations, and coroners.

For

more information, visit: https://ibs.inc/

Forward-Looking

Statements

Some

of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s

ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and

collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent

Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual

results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify

forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”

“plans,” “projects,” “intends,” “potential,” “may,” “could,”

“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty

of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and

unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the

U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.

Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events

or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company

Contact

Intelligent

Bio Solutions Inc.

info@ibs.inc

Investor

& Media Contact

Valter

Pinto, Managing Director

KCSA Strategic Communications

PH: (212) 896-1254

INBS@kcsa.com

Financial

Tables to Follow

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Balance Sheets

As of March 31,

As of June 30,

2026

2025

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents

$ 6,862,204

$ 1,019,909

Accounts receivable, net

878,357

594,614

Inventories

597,469

635,215

Research and development tax incentive receivable

568,600

734,408

Assets held for sale

327,500

Prepaid expenses and other current assets

843,090

826,976

Total current assets

9,749,720

4,138,622

Property and equipment, net

312,276

251,325

Operating lease right-of-use assets

1,801,622

69,520

Intangibles, net

2,999,174

3,790,319

Total assets

$ 14,862,792

$ 8,249,786

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities

Accounts payable and accrued expenses

$ 3,635,719

$ 4,534,246

Current portion of operating lease liabilities

388,746

84,659

Current employee benefit liabilities

586,637

534,990

Notes payable

197,146

Total current liabilities

4,611,102

5,351,041

Employee benefit liabilities, less current portion

40,696

84,921

Operating lease liabilities, less current portion

1,459,678

Total liabilities

6,111,476

5,435,962

Commitments and contingencies

Shareholders’ equity

Common stock, $0.01 par value, 100,000,000 shares authorized, 2,001,185 and 2,001,173 shares issued and outstanding, as of March 31, 2026, respectively; 732,338 and 732,326 shares issued and outstanding, as of June 30, 2025, respectively*

20,012

7,323

Treasury stock, at cost, 12 shares as of March 31, 2026 and June 30, 2025, respectively*

(1 )

Additional paid-in capital*

80,497,637

65,849,823

Accumulated deficit

(71,056,373 )

(62,533,065 )

Accumulated other comprehensive loss

(499,710 )

(327,944 )

Total consolidated Intelligent Bio Solutions Inc. equity

8,961,565

2,996,136

Non-controlling interest

(210,249 )

(182,312 )

Total shareholders’ equity

8,751,316

2,813,824

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 14,862,792

$ 8,249,786

Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15,

2025, throughout the unaudited condensed consolidated financial statements unless otherwise stated.

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Statements of Operations and Other Comprehensive Income (Loss)*

(Unaudited)

Three Months Ended March 31,

Nine Months Ended March 31,

2026

2025

2026

2025

Revenue

$ 1,060,802

$  728,867

$ 3,069,373

$ 2,208,648

Cost of revenue (exclusive of amortization shown separately below)

(525,421 )

(387,499 )

(1,555,962 )

(1,297,366 )

Gross profit

535,381

341,368

1,513,411

911,282

Other income

Government support income

165,695

173,271

431,682

433,039

Operating expenses

Selling, general and administrative expenses

(2,458,605 )

(2,414,639 )

(7,512,388 )

(6,195,490 )

Development and regulatory approval expenses

(893,979 )

(358,351 )

(1,902,261 )

(1,814,047 )

Depreciation and amortization

(290,393 )

(301,978 )

(875,667 )

(907,577 )

Impairment of long-lived assets

(5,200 )

(294,127 )

Total operating expenses

(3,648,177 )

(3,074,968 )

(10,584,443 )

(8,917,114 )

Loss from operations

(2,947,101 )

(2,560,329 )

(8,639,350 )

(7,572,793 )

Other income (expense), net

Interest expense

(4,241 )

(7,919 )

(7,435 )

(21,027 )

Realized foreign exchange gain (loss)

32,258

(113 )

32,258

(914 )

Interest income

49,444

17,687

63,282

92,464

Total other income (expense), net

77,461

9,655

88,105

70,523

Net loss

(2,869,640 )

(2,550,674 )

(8,551,245 )

(7,502,270 )

Net loss attributable to non-controlling interest

(6,928 )

(7,148 )

(27,937 )

23,641

Net loss attributable to Intelligent Bio Solutions Inc.

$ (2,862,712 )

$  (2,543,526 )

$ (8,523,308 )

$ (7,478,629 )

Other comprehensive income (loss)

Foreign currency translation gain (loss)

(233,631 )

116,007

(171,766 )

189,197

Total other comprehensive income (loss)

(233,631 )

116,007

(171,766 )

189,197

Comprehensive loss

(3,103,271 )

(2,434,667 )

(8,723,011 )

(7,313,073 )

Comprehensive loss attributable to non-controlling interest

(6,928 )

(7,148 )

(27,937 )

(23,641 )

Comprehensive loss attributable to Intelligent Bio Solutions Inc.

$ (3,096,343 )

$  (2,427,519 )

$ (8,695,074 )

$ (7,289,432 )

Net loss per share, basic and diluted*

$ (1.80 )

$ (4.41 )

$ (7.54 )

$ (15.92 )

Weighted average shares outstanding, basic and diluted*

1,594,496

577,191

1,129,973

469,849

Common stock and per share amounts have been retroactively

adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the unaudited condensed consolidated financial

statements unless otherwise stated.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 13, 2026

Entity File Number

001-39825

Entity Registrant Name

INTELLIGENT

BIO SOLUTIONS INC.

Entity Central Index Key

0001725430

Entity Tax Identification Number

82-1512711

Entity Incorporation, State or Country Code

Entity Address, Address Line One

135

West

Entity Address, Address Line Two

41st Street

Entity Address, Address Line Three

5th Floor

Entity Address, City or Town

New

York

Entity Address, State or Province

Entity Address, Postal Zip Code

10036

City Area Code

(646)

Local Phone Number

828-8258

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.01 par value

Trading Symbol

INBS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration